Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Illinois Valley Community Hospital
333
mi
from 43215
Peru, IL
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Illinois Valley Community Hospital
333
mi
from 43215
Peru, IL
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Illinois CancerCare - Peru
333
mi
from 43215
Peru, IL
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Illinois CancerCare - Peru
333
mi
from 43215
Peru, IL
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Illinois CancerCare - Princeton
350
mi
from 43215
Princeton, IL
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Illinois CancerCare - Princeton
350
mi
from 43215
Princeton, IL
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Illinois CancerCare - Spring Valley
337
mi
from 43215
Spring Valley, IL
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Illinois CancerCare - Spring Valley
337
mi
from 43215
Spring Valley, IL
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
CCOP - Carle Cancer Center
274
mi
from 43215
Urbana, IL
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
CCOP - Carle Cancer Center
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
St. Francis Hospital Cancer Care Services
163
mi
from 43215
Indianapolis, IN
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
St. Francis Hospital Cancer Care Services
163
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Reid Hospital & Health Care Services
99
mi
from 43215
Richmond, IN
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Reid Hospital & Health Care Services
99
mi
from 43215
Richmond, IN
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
McFarland Clinic, PC
569
mi
from 43215
Ames, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
McFarland Clinic, PC
569
mi
from 43215
Ames, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cedar Rapids Oncology Association
471
mi
from 43215
Cedar Rapids, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cedar Rapids Oncology Association
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Hospital
471
mi
from 43215
Cedar Rapids, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Hospital
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Oncology Associates at Mercy Medical Center
471
mi
from 43215
Cedar Rapids, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Oncology Associates at Mercy Medical Center
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Cancer Center - West Lakes
573
mi
from 43215
Clive, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Cancer Center - West Lakes
573
mi
from 43215
Clive, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
CCOP - Iowa Oncology Research Association
565
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
CCOP - Iowa Oncology Research Association
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Cancer Center at Mercy Medical Center - Des Moines
566
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Cancer Center at Mercy Medical Center - Des Moines
566
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Medical Oncology and Hematology Associates at Mercy Cancer Center
566
mi
from 43215
Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Medical Oncology and Hematology Associates at Mercy Cancer Center
566
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Cancer Center at Mercy Medical Center - North Iowa
569
mi
from 43215
Mason City, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Cancer Center at Mercy Medical Center - North Iowa
569
mi
from 43215
Mason City, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
St. Luke's Regional Medical Center
716
mi
from 43215
Sioux City, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
St. Luke's Regional Medical Center
716
mi
from 43215
Sioux City, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Medical Center - Sioux City
716
mi
from 43215
Sioux City, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Medical Center - Sioux City
716
mi
from 43215
Sioux City, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Siouxland Hematology-Oncology Associates, LLP
715
mi
from 43215
Sioux City, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Siouxland Hematology-Oncology Associates, LLP
715
mi
from 43215
Sioux City, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Methodist West Hospital
573
mi
from 43215
West Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Methodist West Hospital
573
mi
from 43215
West Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Mercy Medical Center-West Lakes
572
mi
from 43215
West Des Moines, IA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Mercy Medical Center-West Lakes
572
mi
from 43215
West Des Moines, IA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Chanute
687
mi
from 43215
Chanute, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Chanute
687
mi
from 43215
Chanute, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Chanute
687
mi
from 43215
Chanute, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Chanute
687
mi
from 43215
Chanute, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Dodge City
925
mi
from 43215
Dodge City, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Dodge City
925
mi
from 43215
Dodge City, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Dodge City
925
mi
from 43215
Dodge City, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Dodge City
925
mi
from 43215
Dodge City, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - El Dorado
756
mi
from 43215
El Dorado, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - El Dorado
756
mi
from 43215
El Dorado, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - El Dorado
756
mi
from 43215
El Dorado, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - El Dorado
756
mi
from 43215
El Dorado, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas - Fort Scott
646
mi
from 43215
Fort Scott, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas - Fort Scott
646
mi
from 43215
Fort Scott, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas-Independence
711
mi
from 43215
Independence, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas-Independence
711
mi
from 43215
Independence, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Kingman
827
mi
from 43215
Kingman, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Kingman
827
mi
from 43215
Kingman, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Lawrence Memorial Hospital
654
mi
from 43215
Lawrence, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Lawrence Memorial Hospital
654
mi
from 43215
Lawrence, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Liberal
988
mi
from 43215
Liberal, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Liberal
988
mi
from 43215
Liberal, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Newton
778
mi
from 43215
Newton, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Newton
778
mi
from 43215
Newton, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Newton
778
mi
from 43215
Newton, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Newton
778
mi
from 43215
Newton, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Parsons
683
mi
from 43215
Parsons, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Parsons
683
mi
from 43215
Parsons, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Parsons
683
mi
from 43215
Parsons, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Parsons
683
mi
from 43215
Parsons, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Pratt
860
mi
from 43215
Pratt, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Pratt
860
mi
from 43215
Pratt, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Pratt
860
mi
from 43215
Pratt, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Pratt
860
mi
from 43215
Pratt, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Salina
782
mi
from 43215
Salina, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Salina
782
mi
from 43215
Salina, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Salina
782
mi
from 43215
Salina, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Salina
782
mi
from 43215
Salina, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Wellington
797
mi
from 43215
Wellington, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Wellington
797
mi
from 43215
Wellington, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Cancer Center of Kansas, PA - Wellington
797
mi
from 43215
Wellington, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Cancer Center of Kansas, PA - Wellington
797
mi
from 43215
Wellington, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Associates in Womens Health, PA - North Review
782
mi
from 43215
Wichita, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Associates in Womens Health, PA - North Review
782
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Associates in Women's Health - Wichita
783
mi
from 43215
Wichita, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Associates in Women's Health - Wichita
783
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Via Christi Cancer Center at Via Christi Regional Medical Center
784
mi
from 43215
Wichita, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Via Christi Cancer Center at Via Christi Regional Medical Center
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated:  8/11/2016
Wesley Medical Center
784
mi
from 43215
Wichita, KA
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Status: Enrolling
Updated: 8/11/2016
Wesley Medical Center
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials